BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• 

  C-suite

  An Early-Career Stand Proved This Young Biotech Exec Had What It Takes

  Ensho Therapeutics CEO Neena Bitritto-Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the one between Eisai and Biogen that led to new Alzheimer’s drugs Aduhelm and Leqembi.

  October 31, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Pain

  Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program

  Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly said that results were not sufficient for advancement of the Asahi Kasei–partnered asset.

  October 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes

  Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.

  October 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IPO

  Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline

  With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.

  October 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Editorial

  Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian

  Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.

  October 31, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  AbbVie’s Immunology Dyad Dominates Again in Q3

  Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.

  October 31, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Deals

  4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront

  Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection.

  October 31, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• Press Releases

  DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

  October 31, 2025

   · 

  20 min read
• Press Releases

  Aptar Reports Third Quarter 2025 Results

  October 31, 2025

   · 

  19 min read
• Press Releases

  QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

  October 31, 2025

   · 

  5 min read